Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis
Open Access
- 2 June 2010
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 62 (10), 1446-1451
- https://doi.org/10.1002/acr.20269
Abstract
Objective To determine if mycophenolate mofetil (MMF) diminishes skin and muscle disease activity in children with juvenile dermatomyositis (DM), thereby permitting a decrease in corticosteroid dose. Methods A retrospective data review for 50 children with juvenile DM (mean ± SD age 12.2 ± 5.0 years) who had received MMF for 12 months identified the following characteristics: 38 (76%) were girls, 39 (78%) were white, 10 (20%) were Hispanic, and 1 (2%) was African American. The MMF dose and frequency, type of infection, white blood cell (WBC) count, corticosteroid dose, and the validated disease activity score (DAS) subscores for skin (DAS‐S) and muscle (DAS‐M) were obtained. Results Twelve months after the start of MMF, the mean ± SD DAS‐S decreased from 5.24 ± 0.29 to 3.72 ± 0.29 (P = 0.001), and the mean ± SD DAS‐M decreased from 2.44 ± 0.39 to 1.17 ± 0.28 (P = 0.002). The mean ± SD prednisone dosage decreased from 0.39 ± 0.06 to 0.23 ± 0.02 mg/kg/day (P = 0.0001), with resumption of linear growth (P = 0.008). The WBC/lymphocyte count was unchanged over the 12 months on MMF. The infection rate was assessed in a subset of 26 children with juvenile DM who were observed for 12 months before the start of MMF and then compared with the ensuing 12 months of MMF therapy. There was no significant difference between the pretreatment period and the first 6 months of MMF therapy (P = 0.44), but the infection rate decreased in months 7–12 (P = 0.001). Conclusion MMF appears to be worthy of consideration as an additional therapeutic modality for treatment of children with juvenile DM. These data suggest that the use of MMF decreases skin and muscle disease activity and is steroid sparing. MMF appears to be well tolerated, but patients should be monitored for infection.This publication has 40 references indexed in Scilit:
- Elevated serum interferon‐α activity in juvenile dermatomyositis: Associations with disease activity at diagnosis and after thirty‐six months of therapyArthritis & Rheumatism, 2009
- The treatment and prognosis of dermatomyositis: An updated reviewJournal of the American Academy of Dermatology, 2008
- Persistent association of nailfold capillaroscopy changes and skin involvement over thirty‐six months with duration of untreated disease in patients with juvenile dermatomyositisArthritis & Rheumatism, 2008
- Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositisBMC Immunology, 2008
- Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositisArthritis & Rheumatism, 2007
- High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosusGenes & Immunity, 2007
- RANKL:Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositisArthritis & Rheumatism, 2007
- MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: Association with muscle involvementClinical Immunology, 2006
- Composition of calcifications in children with juvenile dermatomyositis: Association with chronic cutaneous inflammationArthritis & Rheumatism, 2006
- Duration of illness is an important variable for untreated children with juvenile dermatomyositisThe Journal of Pediatrics, 2006